@aareal

6. Mar 2023 via Twitter

We’ve been believing in our clients for a century. Accompany Christof Winkelmann, our Chief Market Officer on his trip to Amsterdam visiting Klaas Kout from @citizenM. Watch the full video here: https://t.co/CMJ0l0NR4t #Aareal #100years #BuildingYourTomorrow #ClientRelationship pic.twitter.com/csxPmrLXpm— Aareal Bank Group (@aareal) March 6…

@aareal

2. Mar 2023 via Twitter

#Aareal Bank has further improved its capitalisation, with its total capital ratio reaching 24.0 per cent in 2022 (2021: 23.6 per cent). We successfully expanded our funding activities and continued to diversify both funding mix and investor base: https://t.co/7BE1i0dK8n pic.twitter.com/r6wqO4Zet8— Aareal Bank Group (@aareal) March 2, 2023

@aareal

2. Mar 2023 via Twitter

Strong operating performance across all business segments: high portfolio quality – NPLs further reduced. The average deposit volume grew strongly; net interest income at BDS more than doubled. Aareon continued its growth path; SaaS revenues increased: https://t.co/O66nkrbBXf pic.twitter.com/tkTVVzupaB— Aareal Bank Group (@aareal) March 2, …

@aareal

2. Mar 2023 via Twitter

#Aareal Bank posts a 54% increase in consolidated operating profit for 2022. Portfolio quality improved further; net interest income and net commission income both rose significantly. Further increase in earnings expected for our anniversary year 2023: https://t.co/9YALcsQg3C pic.twitter.com/a1cEQoUxPj— Aareal Bank Group (@aareal) March 2, 20…

@eurocrowd

1. Mar 2023 via Twitter

This is a short description of our company⚡ If you want to find out more 👉 click here https://t.co/pmatOcBI9l! pic.twitter.com/e0ER34jLj9— EUROCROWD (@eurocrowd) March 1, 2023

@SachsAssociates

24. Feb 2023 via Twitter

Ultimovacs is an immunotherapy company developing immune-stimulatory vaccines to treat a broad range of cancers. Meet Ultimovacs at #Sachs_ELSFMore info @ https://t.co/hgPC4hxz57#Sachs_ELSF #SSLSW #lifesciences #partnering #bd #licensing pic.twitter.com/vNsZzj4zUm— Sachs Associates (@SachsAssociates) February 24, 2023

@SachsAssociates

24. Feb 2023 via Twitter

Meet Paul Rennert, CEO, President & CSO of Aleta Biotherapeutics at #Sachs_ELSFMore info @ https://t.co/hgPC4hxz57#Sachs_ELSF #SSLSW #lifesciences #partnering #bd #licensing #health #investment #startup #healthcare #innovation #biotech #business #invest #medicine pic.twitter.com/LAtw8WfEld— Sachs Associates (@SachsAssociates) February 24,…

@SachsAssociates

22. Feb 2023 via Twitter

Meet Isabel Ferreira, Chief Business Officer of @versameb at #Sachs_ELSFMore info @ https://t.co/hgPC4hxz57#Sachs_ELSF #SSLSW #lifesciences #partnering #bd #licensing #health #investment #startup #healthcare #innovation #biotech #business #invest #medicine #venturecapital pic.twitter.com/glnEgRE60R— Sachs Associates (@SachsAssociates) Februar…

@SachsAssociates

20. Feb 2023 via Twitter

Renee Aguiar-Lucander has been the CEO of @Calliditas1 since 2017 during which the Company has become publicly listed both in Europe and the US.Meet Renee at #Sachs_ELSFMore info @ https://t.co/hgPC4hxz57#Sachs_ELSF #SSLSW #lifesciences #partnering #bd #licensing #health pic.twitter.com/mpyhgTyVsg— Sachs Associates (@SachsAssociates) February…

@SachsAssociates

17. Feb 2023 via Twitter

Mr. Fazeli brings with him over 25 years of experience conducting equity research as a pharmaceutical analyst.Meet Sam at #Sachs_ELSFMore info @ https://t.co/hgPC4hxz57#Sachs_ELSF #SSLSW #lifesciences #partnering #bd #licensing @SamFazeli8 pic.twitter.com/ylC3Rtf1RL— Sachs Associates (@SachsAssociates) February 17, 2023